Table 1—

Baseline characteristics for patients with diabetes in ASCOT-LLA

AtorvastatinPlacebo
n1,2581,274
Demographics and clinical characteristics
    Female sex289 (23.0)311 (24.4)
    Age (years)
≤60425 (33.8)391 (30.7)
>60833 (66.2)883 (69.3)
Means ± SD63.6 ± 8.564.0 ± 8.2
    White1,131 (89.9)1,163 (91.3)
    Current smoker257 (20.4)258 (20.3)
    Alcohol consumption (units/week)6.7 ± 10.36.6 ± 10.8)
    Systolic blood pressure (mmHg)165.1 ± 17.6164.8 ± 17.1
    Diastolic blood pressure (mmHg)92.9 ± 10.392.4 ± 10.3
    Heart rate (bpm)73.7 ± 13.274.1 ± 13.1
    BMI (kg/m2)30.3 ± 5.030.1 ± 4.7
    Total cholesterol (mmol/l)5.3 ± 0.85.3 ± 0.8
    LDL cholesterol (mmol/l)3.3 ± 0.73.3 ± 0.8
    HDL cholesterol (mmol/l)1.2 ± 0.31.2 ± 0.3
    Triglycerides (mmol/l)1.9 ± 1.01.9 ± 1.0
    Glucose (mmol/l)8.6 ± 2.88.7 ± 2.8
    Creatinine (mmol/l)97.1 ± 15.498.7 ± 18.0
Medical history
    Previous stroke /transient ischemic attack93 (7.4)98 (7.7)
    LVH (according to ECG or ECHO)119 (9.5)111 (8.7)
    ECG abnormalities other than LVH180 (14.3)194 (15.2)
    Peripheral vascular disease70 (5.6)65 (5.1)
    Other significant cardiovascular disease50 (4.0)43 (3.4)
    Number of risk factors (including diabetes)4.1 ± 1.04.0 ± 1.0
Drug therapy
    Oral hypoglycemics645 (51.3)683 (53.6)
    Insulin92 (7.3)96 (7.5)
    Previous antihypertensive treatments
None189 (15.0)209 (16.4)
One557 (44.3)555 (43.6)
Two or more512 (40.7)510 (40.0)
    Lipid-lowering therapy14 (1.1)20 (1.6)
    Aspirin use228 (18.1)208 (16.3)
  • Data are n (%) or means ± SD. ECG, electrocardiogram; ECHO, echocardiogram; LVH, left ventricular hypertrophy.